Xeljanz (tofacitinib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
Enquire now
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Xeljanz (tofacitinib)

How to buy Xeljanz: You can order Xeljanz (tofacitinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Pfizer
Disease Rheumatoid Arthritis
Indication Moderately to severely active rheumatoid arthritis
Mode of Action Inhibitor of Janus kinases (JAKs)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 5 mg

Who is tofacitinib for?

Xeljanz (tofacitinib) is indicated for the treatment of patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate [1] or other nonbiologic disease-modifying antirheumatic drugs [2][3].

Recommended dose

Complete information about Xeljanz (tofacitinib) dosage and administration can be found here: [1][2][3].
The standard dosage is:
  • 5 mg twice daily
Consult your treating doctor for personalised dosing.

What is tofacitinib and how does it work?

Xeljanz (tofacitinib) is an inhibitor of Janus kinases (JAKs) used to treat adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate [1][2][3].

The active substance in Xeljanz, tofacitinib, works by blocking the action of enzymes known as Janus kinases which play an important role in the process of inflammation and joint damage that occurs in rheumatoid arthritis. By blocking their action, tofacitinib helps reduce the inflammation and other symptoms of the disease [4].

What is tofacitinib's approval status?

Xeljanz (tofacitinib) was approved by, among others:
  • FDA (USA) on November 6, 2012 [5]
  • EMA (EU) on March 22, 2017 [4]
  • TGA (AUS) on February 5, 2015 [3]
for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

The approvals were based on 6 studies in over 4,200 patients with rheumatoid arthritis which have shown the effectiveness of tofacitinib at reducing joint pain and swelling, improving joint movement and slowing down joint damage [1]. An important measure in patients with rheumatoid arthritis is the ACR 20, 50 or 70 which is a criteria to measure the improvement of patients of 20 %, 50 % or 70 % based on measures as swollen joint count, tender joint count, patient assessment of global status, acute phase reactant (dramatic increase in hepatic synthesis of plasma proteins which accompanies acute phases of tissue injury and inflammation), health professional assessment of global status, physical function, and pain [6].
In the clinical studies patients treated with either 5 or 10 mg Xeljanz (tofacitinib) twice daily had ACR20, ACR50, and ACR70 response rates over two times higher than placebo. Higher ACR20 response rates were observed within 2 weeks compared to placebo and were consistent at 6 and 12 months [2]. Detailed information about the clinical studies can be found here: [1][2][3].

The most commonly reported adverse reactions were upper respiratory tract infections, headache, diarrhea, and nasopharyngitis [1][2][3].
[1] Summary of Product Characteristics [EMA]: Xeljanz (tofacitinib), Pfizer Ltd., Mar. 2017.
[2] Summary of Product Characteristics [FDA]: Xeljanz (tofacitinib), Pfizer Inc., Feb. 2016.
[3] Summary of Product Characteristics [TGA]: Xeljanz (tofacitinib), Pfizer Australia Pty Ltd, Feb. 2017.
[4] EMA. Human Medicines: Xeljanz (tofacitinib), 31/03/2017, cited on 24/05/2017.
[5] Drugs.com. Xeljanz (tofacitinib). (last update: 25/03/2016), cited on 24/05/2017.
[6] Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative “patient only” indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(39):109–113.

"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Share our website

Follow us

DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.